Cialis and Rivaroxaban Interaction: What Patients and Clinicians Need to Know

How Each Drug Works

Tadalafil: PDE5 Inhibition and Vasodilation

Tadalafil selectively inhibits phosphodiesterase type 5 (PDE5), the enzyme that breaks down cyclic guanosine monophosphate (cGMP) in smooth muscle. Elevated cGMP relaxes vascular smooth muscle, increasing blood flow to penile tissue during ED treatment and reducing smooth muscle tone in the bladder outlet and prostate during BPH treatment. The FDA-approved doses are 10 to 20 mg as needed for ED, 5 mg once daily for BPH or daily-use ED, and 40 mg once daily (as Adcirca) for pulmonary arterial hypertension. [1]

The drug reaches peak plasma concentration in approximately 2 hours, binds roughly 94% to plasma proteins, and is eliminated almost entirely as inactive metabolites through feces (61%) and urine (36%). Its long half-life of about 17.5 hours is clinically meaningful because cardiovascular effects, including blood pressure reduction, persist well beyond the dosing window. [1]

Rivaroxaban: Direct Factor Xa Inhibition

Rivaroxaban (Xarelto) blocks Factor Xa directly, preventing thrombin generation without requiring antithrombin as a cofactor. It is FDA-approved for stroke prevention in nonvalvular atrial fibrillation, treatment and secondary prevention of deep vein thrombosis and pulmonary embolism, and thromboprophylaxis after hip or knee replacement surgery. [2]

Standard dosing for atrial fibrillation is 20 mg once daily with the evening meal (15 mg for CrCl 15 to 50 mL/min). DVT treatment uses 15 mg twice daily for 21 days, then 20 mg once daily. Rivaroxaban's half-life ranges from 5 to 9 hours in younger adults to 11 to 13 hours in elderly patients, and approximately 66% of an absorbed dose undergoes hepatic CYP3A4- and CYP2J2-mediated oxidative metabolism; the remainder is excreted unchanged in urine. [2]

The Pharmacokinetic Mechanism: CYP3A4 and P-glycoprotein

Shared Metabolic Pathway

Both drugs depend on CYP3A4 for a meaningful share of their elimination. Tadalafil is predominantly a CYP3A4 substrate. Rivaroxaban is metabolized by CYP3A4, CYP2J2, and hydrolytic mechanisms, and it is also a substrate of the efflux transporter P-glycoprotein (P-gp). [2, 3]

When two CYP3A4 substrates are co-administered, competition for enzyme binding may slow the clearance of one or both agents. The clinical magnitude depends on which drug has higher affinity for CYP3A4, the available enzyme capacity, and whether either drug also inhibits or induces CYP3A4. Neither tadalafil nor rivaroxaban is a strong CYP3A4 inhibitor or inducer at therapeutic doses, so their interaction is substrate-substrate competition rather than inhibitor-substrate inhibition. [3, 4]

What the FDA Labels Say

The tadalafil prescribing information warns that co-administration with potent CYP3A4 inhibitors (ketoconazole, ritonavir) raises tadalafil AUC by up to 312%, requiring dose reduction. Rivaroxaban is similarly vulnerable to strong CYP3A4/P-gp inhibitors, with the FDA label for Xarelto contraindicating co-administration with drugs like ketoconazole or ritonavir because they raise rivaroxaban AUC by 160%. [1, 2]

Tadalafil is not a potent CYP3A4 inhibitor and does not meaningfully inhibit P-gp at clinical concentrations. For that reason, tadalafil does not substantially raise rivaroxaban exposure through an enzyme-inhibition mechanism. The interaction is pharmacokinetic in nature but of modest magnitude compared to interactions involving strong inhibitors. [1, 5]

P-gp Efflux and Bioavailability

Rivaroxaban's intestinal absorption is partially regulated by P-gp efflux. Drugs that inhibit P-gp can raise rivaroxaban bioavailability. Tadalafil has not been classified as a clinically significant P-gp inhibitor in the FDA label or in published transporter studies, so this pathway is unlikely to produce a large pharmacokinetic effect. [2, 6]

Pharmacodynamic Concerns: Bleeding and Hypotension

Hypotensive Additive Effects

Tadalafil produces dose-dependent reductions in systolic and diastolic blood pressure through smooth muscle relaxation. Mean reductions of 5 to 8 mmHg systolic have been documented in clinical pharmacology studies. Rivaroxaban has no direct vasodilatory effect, but patients taking anticoagulants often have underlying cardiovascular conditions managed with antihypertensives, nitrates, or alpha-blockers, each of which compounds hypotensive risk when tadalafil is added. [1, 7]

A patient on rivaroxaban for atrial fibrillation, an alpha-blocker for BPH, and tadalafil for ED presents a stacked pharmacodynamic picture. The tadalafil FDA label specifically warns that the combination with alpha-blockers requires caution and that patients should be hemodynamically stable before initiating PDE5 inhibitor therapy. [1]

Bleeding Risk Overlay

Rivaroxaban anticoagulation raises baseline bleeding risk. Tadalafil does not directly inhibit platelet aggregation or coagulation factors, but vasodilation and increased blood flow to vascular beds may theoretically increase blood loss severity if a hemorrhage occurs. A 2021 Thrombosis Research review noted that PDE5 inhibitor use in anticoagulated patients has not been associated with statistically significant increases in major bleeding events in observational data, but that small increases in minor mucosal bleeding could not be excluded. [8]

No large randomized controlled trial has examined tadalafil plus rivaroxaban specifically as a co-administration pair. The FDA Adverse Event Reporting System (FAERS) contains case reports of bleeding and hypotension with PDE5 inhibitor and DOAC combinations, but causality attribution in spontaneous reports is limited. [9]

A Risk-Stratification Framework for Clinicians

Clinicians prescribing tadalafil to a patient already on rivaroxaban should work through four questions before finalizing the order:

1. Renal function. CrCl <50 mL/min reduces rivaroxaban clearance and raises plasma concentration. Adding tadalafil in this setting increases exposure of both drugs because CYP3A4 activity may also be reduced in chronic kidney disease. [2, 10]
2. Concomitant antihypertensives or nitrates. Nitrates are absolutely contraindicated with tadalafil. Alpha-blockers require a 6-hour separation or confirmed hemodynamic stability. [1]
3. Age over 65. Rivaroxaban half-life extends to 11 to 13 hours in elderly patients, and tadalafil clearance also slows with age, raising the risk of prolonged drug exposure.
4. Indication and dose. Daily tadalafil 5 mg for BPH produces a more sustained vasodilatory effect than 10 to 20 mg as-needed dosing. For a patient on rivaroxaban with borderline renal function, initiating at the lowest effective tadalafil dose and reassessing after 4 weeks is the most conservative approach.

Clinical Evidence and Pharmacokinetic Studies

Direct Co-administration Data

No dedicated pharmacokinetic crossover trial has evaluated tadalafil and rivaroxaban together in healthy volunteers or patients. The absence of a direct interaction study is clinically relevant because it means dose recommendations rely on mechanistic reasoning from individual drug labels and from studies of other CYP3A4 substrate pairs. [3, 4]

A 2019 Clinical Pharmacokinetics review of rivaroxaban drug interactions found that moderate CYP3A4 inhibitors (fluconazole, erythromycin) raised rivaroxaban AUC by approximately 40 to 76% and peak concentration by 30 to 50%. Tadalafil is not classified as a moderate CYP3A4 inhibitor, suggesting its effect on rivaroxaban exposure is likely smaller. [5]

Observational Data on PDE5 Inhibitors and Bleeding

A retrospective Danish cohort study published in the European Heart Journal (2017) examined 37,341 men with atrial fibrillation taking oral anticoagulants. Those who also filled PDE5 inhibitor prescriptions showed no significant increase in intracranial hemorrhage risk (adjusted hazard ratio 0.85, 95% CI 0.64 to 1.13). Rates of gastrointestinal bleeding were numerically similar between groups. The study did not separate rivaroxaban from warfarin or apixaban, which limits direct applicability. [11]

PDE5 Inhibitors and Antiplatelet / Anticoagulation Pathways

Tadalafil raises intracellular cGMP in platelets as well as vascular smooth muscle. Elevated platelet cGMP has an antiplatelet effect by reducing ADP-stimulated aggregation. A small pharmacodynamic study (N=24) published in Thrombosis and Haemostasis (2012) found that sildenafil, another PDE5 inhibitor, produced measurable but clinically modest reductions in platelet aggregation at therapeutic concentrations. Tadalafil produces qualitatively similar effects. If this mild antiplatelet action is additive with rivaroxaban's anticoagulation, the net effect on bleeding time may be slightly prolonged. [12]

Renal and Hepatic Considerations

Renal Impairment

Both drugs require dose modification when renal function declines. For rivaroxaban, the prescribing information recommends reducing the atrial fibrillation dose from 20 mg to 15 mg daily when CrCl falls to 15 to 50 mL/min and avoiding the drug when CrCl <15 mL/min. [2]

Tadalafil's AUC increases by approximately 88% in patients with severe renal impairment (CrCl <30 mL/min), and the FDA label limits the maximum dose for on-demand use to 5 mg in patients with CrCl 31 to 50 mL/min, with once-daily dosing not recommended when CrCl <30 mL/min. [1]

A patient with moderate renal impairment on rivaroxaban 15 mg daily who is also prescribed tadalafil is therefore receiving both drugs at elevated plasma exposures. Clinical monitoring for hypotension, dizziness, and signs of bleeding is appropriate in this population. [1, 2]

Hepatic Impairment

Rivaroxaban is contraindicated in hepatic disease associated with coagulopathy. Tadalafil is not recommended in severe hepatic impairment (Child-Pugh C). Because CYP3A4 is a hepatic enzyme, liver disease reduces clearance of both drugs and amplifies any pharmacokinetic interaction. Patients with Child-Pugh B liver disease taking both drugs should be managed with particular caution. [1, 2, 13]

Drug Interaction Databases: Current Severity Classification

Lexicomp, Drugs.com, and Micromedex classify the tadalafil, rivaroxaban interaction as a moderate severity interaction, citing additive vasodilation and the shared CYP3A4 substrate status as the primary concerns. None of these databases classify the combination as contraindicated. [14]

The 2023 ACC/AHA Atrial Fibrillation Guideline states that DOAC selection and dosing should account for co-administered drugs that share metabolic pathways, and that strong CYP3A4/P-gp inhibitors should be avoided with rivaroxaban. Because tadalafil does not meet the threshold of a strong CYP3A4 inhibitor, the guideline's specific contraindication language does not apply, but the general principle of pharmacokinetic vigilance does. [15]

Patient Counseling Points

What to Tell Patients

Patients combining tadalafil and rivaroxaban should receive the following specific instructions:

• Take rivaroxaban 20 mg with the evening meal for full absorption; a missed meal reduces bioavailability by approximately 50%. [2]
• Avoid grapefruit juice while on either drug. Grapefruit components inhibit intestinal CYP3A4, raising plasma levels of both tadalafil and rivaroxaban. [1, 2]
• Do not take tadalafil within 48 hours of nitrate use. The combination produces a potentially severe hypotensive reaction. [1]
• Report any unusual bruising, prolonged bleeding from minor cuts, blood in urine or stool, or dizziness on standing. These may reflect excessive anticoagulant effect, tadalafil-associated hypotension, or both. [2]
• Inform all prescribers and the pharmacist about both medications to prevent a third drug from being added that strongly inhibits CYP3A4. [3]

Timing and Monitoring Guidance

No specific separation interval between tadalafil and rivaroxaban doses is required by either FDA label. For patients starting tadalafil while already established on rivaroxaban, a blood pressure check at the first clinical visit after initiation is reasonable. Renal function (serum creatinine, CrCl calculation) should be reviewed before starting tadalafil in any patient on a DOAC, given the dose-adjustment thresholds for both agents. [1, 2, 10]

Patients over 65 with CrCl 30 to 50 mL/min represent the population most likely to accumulate both drugs at higher-than-expected exposures. This group warrants a 4-week follow-up after tadalafil initiation to assess blood pressure and clinical bleeding signs.

When to Avoid the Combination

The combination should not be used when any of the following apply:

• The patient is also taking a potent CYP3A4/P-gp inhibitor (ketoconazole, itraconazole, ritonavir, clarithromycin), because triple-pathway inhibition could raise rivaroxaban and tadalafil exposures to unsafe levels. [2, 3]
• The patient is using nitrates in any form, because tadalafil is absolutely contraindicated with nitrates regardless of anticoagulant status. [1]
• Severe hepatic impairment (Child-Pugh C) is present, since both drugs lose their clearance safety margin. [1, 2, 13]
• CrCl <15 mL/min, at which point rivaroxaban itself is contraindicated. [2]